|
APOE ε genotypes
|
T-cholesterol (mg/dL)
|
Beta (95 % CI)
|
P valuea
|
LDL-C (mg/dL)
|
Beta (95 % CI)
|
P valuea
|
Triglyceride (mg/dL)
|
Beta (95 % CI)
|
P valuea
|
HDL-C (mg/dL)
|
Beta (95 % CI)
|
P valuea
|
CRP (mg/L)
|
Beta (95 % CI)
|
P valuea
|
|---|
|
ε2 (n = 81)
|
181.7 ± 36.2
|
0.03 (0.01–0.04)
|
4.24 × 10−5
|
96.5 ± 27.6
|
0.05 (0.03–0.07)
|
1.94 × 10−7
|
138.4 ± 114.1
|
0.03 (−0.003–0.06)
|
0.054
|
57.3 ± 15.2
|
−0.02 (−0.03 to −0.002)
|
0.008
|
1.09 ± 1.70
|
−0.08 (−0.14 to −0.01)
|
0.018
|
|
ε3 (n = 399)
|
200.2 ± 35.1
|
118.1 ± 32.1
|
138.3 ± 121.1
|
55.5 ± 14.7
|
1.13 ± 1.33
|
|
ε4 (n = 96)
|
205.0 ± 36.9
|
122.3 ± 32.0
|
165.5 ± 119.7
|
51.7 ± 11.8
|
0.88 ± 1.33
|
|
ε2 (n = 81)
|
181.7 ± 36.2
|
0.05 (0.03–0.06)
|
6.65 × 10−6
|
96.5 ± 27.6
|
0.09 (0.06–0.12)
|
5.12 × 10−9
|
138.4 ± 114.1
|
0.01 (−0.05–0.06)
|
0.779
|
57.3 ± 15.2
|
−0.02 (−0.04–0.01)
|
0.172
|
1.09 ± 1.70
|
0.02 (−0.09–0.12)
|
0.782
|
|
Non-ε2 (n = 495)
|
201.1 ± 35.5
|
118.9 ± 32.1
|
143.6 ± 121.2
|
54.8 ± 14.2
|
1.08 ± 1.33
|
|
ε4 (n = 96)
|
205.0 ± 36.9
|
0.02 (−0.002–0.03)
|
0.068
|
122.3 ± 32.0
|
0.03 (0.004–0.06)
|
0.031
|
165.5 ± 119.7
|
0.06 (0.01–0.11)
|
0.018
|
51.7 ± 11.8
|
−0.02 (−0.04 to −0.001)
|
0.020
|
0.88 ± 1.33
|
−0.19 (−0.28 to −0.09)
|
2.12 × 10−4
|
|
Non-ε4 (n = 480)
|
197.1 ± 35.9
|
114.5 ± 32.4
|
138.3 ± 119.9
|
55.8 ± 14.7
|
1.12 ± 1.40
|
- ε2 (ε2ε2 and ε2ε3); ε3 (ε3ε3); ε4 (ε3ε4 and ε4ε4)
-
aThe multiple linear regressions were adjusted for age, sex, BMI, current smoking status, and anti-hypertensive and anti-diabetic treatments
